InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

. . . InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update September 30, 2024 8:00 AM EDT | Source: InMed Pharmaceuticals Advances INM-901 program targeting several biological pathways associated with Alzheimer's disease Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration $4.6M revenues in fiscal year 2024, representing a 11% increase over the previous fiscal year Vancouver, British Columbia--(Newsfile ...